Atnahs Pharma Denmark ApS
APSActiveCVR 36699051Ørestads Boulevard 108, 2300 København SWholesale of pharmaceutical and medical goods· NACE 4646Est. 2015 · 11 years old— employees
Loading company…
Overview
Atnahs Pharma Denmark ApS is a Danish APS based in København S, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2015, the company reported revenue of DKK 52.6m in its latest annual filing.
Revenue 2026
52.6M DKK
−26% vs 2025
EBITDA margin
−3.0 %
−217% vs 2025
Net profit 2026
0M DKK
-74% vs 2025
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
6.3 %
WeakAmong the 30% lowest rated companies in the industry
20222026
Liquidity ratioCurrent assets ÷ Short-term debt
1.1×
WeakAmong the 40% lowest rated companies in the industry
20222026
Return on assets (ROA)Net profit ÷ Total assets × 100
0.0 %
WeakAmong the 40% lowest rated companies in the industry
20222026
EBITDA — year on year
DKK millionsKey figures
Annual report 2026| Revenue | 52.6M DKK | -26% |
| EBITDA | -1.6M DKK | -217% |
| Net profit | 0M DKK | -74% |
| Total assets | 33.1M DKK | -35% |
| Equity | 2.1M DKK | +1% |
| Employees | — | — |
Company information
Legal name
Atnahs Pharma Denmark ApS
CVR number
36699051
Legal form
Anpartsselskab
NACE code
Founded
27 March 2015 · 11 years
Share capital
DKK 50,000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2026-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens medlemmer hver for sig eller af en direktør alene.
Company purpose
Selskabets formål er at drive handelsvirksomhed med farmaceutiske produkter, herunder udvikling, salg, distribution og markedsføring af farmaceutiske produkter og dermed beslægtet virksomhed.
(no translation available)
Address
Ørestads Boulevard 108, 2300 København S
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2026), Atnahs Pharma Denmark ApS reported revenue of DKK 52.6m, a decrease of 26% on the year before. The figures on this page draw on 5 annual filings covering 2022 to 2026. The bottom line showed a net profit of DKK 12.5k, and the EBITDA margin stood at -3%.
At the end of 2026, equity financed 6.3% of the balance sheet, and current assets covered short-term debt 1.1 times.
Financials
Revenue
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 52,584 | 71,428 | 91,292 | 517,226 | 9,762 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1,600 | 1,363 | 929 | -19,380 | 9,762 |
| Depreciation & amort. | -225 | -60 | 2 | -0 | -0 |
| EBIT | -1,825 | 1,303 | 927 | -19,380 | 9,762 |
| Net financials | 1,864 | -1,240 | -901 | 38,152 | -6,115 |
| Profit before tax | 39 | 63 | 27 | 18,771 | 3,647 |
| Tax | 26 | 15 | 6 | 4,051 | -0 |
| Net profit | 12 | 48 | 20 | 14,720 | 3,647 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | 33,137 | 51,236 | 66,995 | 407,346 | 202,928 |
| Equity | 2,094 | 2,082 | 2,016 | 14,862 | 142 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 30,417 | 47,387 | 64,964 | 392,395 | 202,780 |
| Total debt | 30,417 | 47,387 | 64,964 | 392,395 | 202,780 |
Financial ratios
5-year trendEBITDA margin
-3.0 %
20222026
Equity ratio
6.3 %
WeakAmong the 30% lowest rated companies in the industry
20222026
Return on equity
0.6 %
WeakAmong the 30% lowest rated companies in the industry
20222026
Net profit margin
0.0 %
WeakAmong the 40% lowest rated companies in the industry
20222026
Asset turnover
1.59×
AverageAround the average of companies in the same industry
20222026
Debt / equity
14.82×
Very weakAmong the 10% lowest rated companies in the industry
20222026
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 20% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginWeak
Among the 30% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginWeak
Among the 40% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 30% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 30% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 10% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 30% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 30% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 40% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 30% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtAverage
Around the average of companies in the same industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverAverage
Around the average of companies in the same industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2026Filed via CVR / Virk · Period 2025-04-01 – 2026-03-31
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CM Management | Management | 2026 |
Former (5)
NB Management | Management | 2025 – 2026 |
JS Management | Management | 2023 – 2025 |
AV Management | Management | 2019 – 2023 |
SA Management | Management | 2016 – 2019 |
LJ Management | Management | 2015 – 2016 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MM Chairman | Chairman | 2026 |
TJ Board of Directors | Board of Directors | 2026 |
CM Board of Directors | Board of Directors | 2026 |
Former (14)
NB Board of Directors | Board of Directors | 2019 – 2026 |
ZJ Board of Directors | Board of Directors | 2025 – 2025 |
JS Board of Directors | Board of Directors | 2023 – 2025 |
MJ Board of Directors | Board of Directors | 2019 – 2019 |
DV Deputy Chairman | Deputy Chairman | 2016 – 2019 |
FA Board of Directors | Board of Directors | 2021 – 2023 |
JC Board of Directors | Board of Directors | 2021 – 2025 |
AV Chairman | Chairman | 2016 – 2026 |
AT Board of Directors | Board of Directors | 2019 – 2021 |
SA Board of Directors | Board of Directors | 2019 – 2021 |
RB Board of Directors | Board of Directors | 2019 – 2022 |
JW Board of Directors | Board of Directors | 2021 – 2023 |
AC Board of Directors | Board of Directors | 2016 – 2020 |
SP Board of Directors | Board of Directors | 2025 – 2026 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Atnahs Pharma UK Limited | Company | 100% | 100% | 2018 |
| Individual | 33.33–49.99% | 33.33–49.99% | 2018 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Atnahs Pharma UK Limited
Atnahs Pharma Denmark ApS Board network connections
Board members of Atnahs Pharma Denmark ApS also hold positions in 16 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svend Aage Johansen | Management | 8 companiesMany roles |
| Lisbet Johansen | Management | 4 companies |
| James Sang Bum Lee | Management | 1 company |
| Christoph Michael Habereder | Management | 1 company |
| Mohammad Muqtadir Samy | Chairman | 1 company |
| Twan Johannes Anna Nouwen | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of Atnahs Pharma Denmark ApS?
Atnahs Pharma Denmark ApS is registered with CVR / Virk under CVR 36699051.
What is the revenue of Atnahs Pharma Denmark ApS?
Atnahs Pharma Denmark ApS reported revenue of DKK 52.6m in 2026.
Who is the chairman of Atnahs Pharma Denmark ApS?
Mohammad Muqtadir Samy chairs the board of Atnahs Pharma Denmark ApS, in role since 2026.
Where is Atnahs Pharma Denmark ApS headquartered?
Atnahs Pharma Denmark ApS's registered address is Ørestads Boulevard 108, 5. tv.